PSYCHEMEDICS MICROPLATE EIA FOR OXYCODONE IN HAIR

K123799 · Psychemedics Corp. · DJG · Feb 8, 2013 · Clinical Toxicology

Device Facts

• Record ID: K123799
• Device Name: PSYCHEMEDICS MICROPLATE EIA FOR OXYCODONE IN HAIR
• Applicant: Psychemedics Corp.
• Product Code: DJG · Clinical Toxicology
• Decision Date: Feb 8, 2013
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 862.3650
• Device Class: Class 2

Indications for Use

The Psychemedics Microplate EIA for Oxycodone is an enzyme immunoassay (EIA) for the preliminary qualitative detection of the opiate oxycodone in human head and body hair using an oxycodone calibrator at 2 ng /10 mg hair cutoff for the purpose of identifying oxycodone use. This is an in vitro diagnostic device intended exclusively for Psychemedics use only and is not intended for sale to anyone. The Psychemedics Microplate EIA oxycodone assay provides only a preliminary analytical test result. A more specific alternative chemical method must be used in order to obtain a confirmed analytical result. Gas or Liquid Chromatography/Mass Spectrometry (GC/MS or LC/MS or LC/MS/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be exercised with any drug of abuse test result, particularly when the preliminary result is positive.

Device Story

Device performs qualitative screening for oxycodone in human head and body hair; utilizes pre-analytical hair treatment to convert solid matrix to liquid; screening assay uses enzyme immunoassay (EIA) in microplate format. Input: hair sample extract; primary antibody; secondary antibody-HRP conjugate; TMB substrate. Principle: competitive binding; drug in sample competes with drug-BSA conjugate on microplate wells for antibody binding; absorbance measured at 450/650 nm is inversely proportional to drug concentration. Output: preliminary qualitative result (positive/negative). Used in Psychemedics laboratory; operated by trained personnel. Results require confirmation by GC/MS or LC/MS/MS before clinical decision-making. Benefits: rapid screening for oxycodone use.

Clinical Evidence

No clinical studies performed. Bench testing included precision (intra-assay and inter-assay) using spiked hair samples, analytical specificity (cross-reactivity), and interference studies (cosmetic treatments). Method comparison study tested 161 donor hair samples against LC/MS/MS reference method.

Technological Characteristics

Enzyme immunoassay (EIA) using microplate wells coated with oxycodone-BSA conjugate. Reagents: polyclonal rabbit anti-oxycodone, goat anti-rabbit HRP-conjugated secondary antibody, TMB substrate, HCl stop solution. Requires microplate reader (450/650 nm) and plate washer. Qualitative assay; results normalized as B/B0 x 100.

Indications for Use

Indicated for the preliminary qualitative detection of oxycodone in human head and body hair to identify oxycodone use. Intended for use by Psychemedics only; requires confirmatory testing via GC/MS or LC/MS/MS for positive results.

Regulatory Classification

Identification

An opiate test system is a device intended to measure any of the addictive narcotic pain-relieving opiate drugs in blood, serum, urine, gastric contents, and saliva. An opiate is any natural or synthetic drug that has morphine-like pharmocological actions. The opiates include drugs such as morphine, morphine glucoronide, heroin, codeine, nalorphine, and meperedine. Measurements obtained by this device are used in the diagnosis and treatment of opiate use or overdose and in monitoring the levels of opiate administration to ensure appropriate therapy.

Special Controls

*Classification.* Class II (special controls). An opiate test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (*e.g.,* programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military).

Predicate Devices

• RapidOne-OXY Test (k014101)

Submission Summary (Full Text)

{0}

1

# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number:
k123799

B. Purpose for Submission:
New device

C. Measurand:
Oxycodone

D. Type of Test:
Qualitative enzyme immunoassay (EIA)

E. Applicant:
Psychemedics Corporation

F. Proprietary and Established Names:
Psychemedics Microplate EIA for Oxycodone in Hair

G. Regulatory Information:

| Product Code | Classification | Regulation Section | Panel |
| --- | --- | --- | --- |
| DJG | Class II | 862.3650 – Opiate test system | 91-Toxicology |

H. Intended Use:

1. Intended use(s):
See indications for use below.

{1}

2. Indication(s) for use:

The Psychemedics Microplate EIA for Oxycodone is an enzyme immunoassay (EIA) for the preliminary qualitative detection of oxycodone in human head and body hair using a oxycodone calibrator at 2 ng /10 mg hair cutoff for the purpose of identifying oxycodone use. This is an in vitro diagnostic device intended exclusively for Psychemedics use only and is not intended for sale to anyone.

The Psychemedics Microplate EIA for oxycodone assay provides only a preliminary analytical test result. A more specific alternative chemical method must be used in order to obtain a confirmed analytical result. Gas or Liquid Chromatography/Mass Spectrometry (GC/MS or LC/MS or LC/MS/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be exercised with any drug of abuse test result, particularly when the preliminary result is positive.

Psychemedics plans to perform this test at one site. Psychemedics has not performed an evaluation of reproducibility at different sites.

3. Special conditions for use statement(s):

This assay is for over the counter use.

4. Special instrument requirements:

The device is for use with a microplate reader capable of measuring at 450 and 650 nm. Plate washing also requires an instrument specifically designed to effectively and reproducibly wash all wells uniformly.

I. Device Description:

The test consists of two parts; a pre-analytical hair treatment procedure (to convert the solid matrix of hair to a measurable liquid matrix) and the screening assay, the Psychemedics Microplate EIA for Oxycodone. The drug is recovered from the hair using a patented method. The screening portion of the test system consists of (1) microplate wells coated with multiple drugs including oxycodone conjugated to bovine serum albumin (BSA), polyclonal rabbit anti-oxycodone, goat anti-rabbit secondary antibody conjugated to HRP (horseradish peroxidase), substrate [3, 3', 5, 5' tetramethylbenzidine (TMB)], HCl to acidify the final reaction, and wash buffer for washing the plates. Absorbance in the wells is read with a microplate reader.

J. Substantial Equivalence Information:

1. Predicate device name(s):

Omega Laboratories Hair Drug Screening for Opiates, Oxycodone and Hydrocodone

{2}

2. Predicate K number(s):

K103161

3. Comparison with predicate:

| Item | Candidate Device | Predicate |
| --- | --- | --- |
| Sample matrix | Head and body hair | Same |
| Method of measurement | Microplate reader | Same |
| Cutoff | 2 ng morphine/10 mg hair | 3 ng morphine/10 mg hair |
| Test Principle | EIA | RIA |

## K. Standard/Guidance Document Referenced (if applicable):

Draft Guidance for Industry and FDA Staff: "Premarket Submission and Labeling Recommendations for Drug of Abuse Screening Tests," Issued on December 2, 2003.

## L. Test Principle:

Hair sample extracts and primary antibody are combined in the wells and incubated. After washing, secondary antibody-HRP is added and incubated. After washing, substrate is added, and, after a final incubation, the wells are acidified and read with the microplate reader. Results are normalized by expression as B/B0 x 100. If morphine or related opiates are present in the sample, less primary antibody will be bound to the solid-phase antigen, thereby resulting in less binding of HRP-labeled secondary antibody; the absorbance produced is inversely proportional to the amount of opiates in the sample (specimen, calibrator or control).

## M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

Precision studies were performed by taking calibrator and control materials, to prepare spike solutions of negative head and body hair samples at the following concentrations; negative, $\pm 75\%$, $\pm 50\%$, $\pm 25\%$ and $100\%$ of the cutoff. The concentration of each sample was confirmed by LC/MS/MS. Intra-assay precision was performed in one run, 15 replicates and inter-assay precision was performed once a day over 5 non-consecutive days.

{3}

The results are presented in the tables below:

Intra-assay

| Percent of Cut-off | Replicate Number | Pos/Neg |
| --- | --- | --- |
| -100% | 15 | 0/15 |
| -75% | 15 | 0/15 |
| -50% | 15 | 0/15 |
| -25% | 15 | 0/15 |
| Cutoff | 15 | 9/6 |
| +25% | 15 | 15/0 |
| +50% | 15 | 15/0 |
| +75% | 15 | 15/0 |
| +100% | 15 | 15/0 |

Inter-assay

| Percent of Cut-off | Replicate Number | Pos/Neg |
| --- | --- | --- |
| -100% | 75 | 0/75 |
| -75% | 75 | 0/75 |
| -50% | 75 | 0/75 |
| -25% | 75 | 0/75 |
| Cutoff | 75 | 41/34 |
| +25% | 75 | 75/0 |
| +50% | 75 | 75/0 |
| +75% | 75 | 75/0 |
| +100% | 75 | 75/0 |

b. Linearity/assay reportable range:

Not applicable. This is a qualitative assay.

{4}

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

Psychemedics manufactures calibrators and control materials using drug stocks purchased from a commercial vendor. Each lot of drug is received with its specific certificate of analysis. The commercially obtained stock is made into the calibrators and controls to the desired concentrations. The concentrations are confirmed by LC/MS/MS.

Stability studies for both controls and calibrators have been conducted. Protocols and acceptance criteria were described and found to be acceptable. The manufacturer claims the following expiration date for both controls and calibrators:

When stored at less than or equal to -20 °C for calibrators and -10 °C for quality controls the product is stable for 12 months.

d. Detection limit:

Not required since this is a qualitative test

e. Analytical specificity:

Cross-reactivity was established by spiking various concentrations of each substance into drug-free head and body samples and evaluating the result against the cutoff control.

Results are expressed as a concentration of compound required to produce a response approximately equivalent to the cutoff concentration of the assay. The results are presented in the table below:

| Compound | Approximate concentration of compound (pg/mg) Equivalent to 2 ng /10 mg hair Oxycodone Cutoff | % Cross reactivity |
| --- | --- | --- |
| Codeine | >1000 | <0.2% |
| Hydromorphone | 1000 | 0.2% |
| Acetylcodeine | >1000 | <0.2% |
| 6-Acetylmorphine | >1000 | <0.2% |
| Morphine | >1000 | <0.2% |
| Methadone | >1000 | <0.2% |
| Dihydrocodeine | >1000 | <0.2% |
| Ethylmorphine | >1000 | <0.2% |

{5}

| Dihydromorphine | >1000 | <0.2% |
| --- | --- | --- |
| Naloxone | >1000 | <0.2% |
| Naltrexone | >1000 | <0.2% |
| Nalorphine | >1000 | <0.2% |
| Propoxyphene | >1000 | <0.2% |
| Morphine Glucuronide | >1000 | <0.2% |
| Meperidine | >1000 | <0.2% |
| Hydrocodone | 26 | 7.7 |
| Oxymorphone | 2 | 100 |

Structurally unrelated:

Negative hair samples were spiked with morphine to -50%, and +50% of the cutoff. Structurally related and unrelated compounds were added to methanol to a concentration of 100 ng/10 mg hair then added to the negative hair sample. The following compounds do not cause interference at +/- 50% of the cutoff; Anhydroecgonine methyl ester, Atropine, Bupropion, Cotinine, Cannabinol, Chlorpheniramine maleate, O-Desmethyvenlafaxine, Desipramine, Doxylamine succinate, 1S, 2R Ephedrine, Nicotine, Naproxen, Nortriptyline, Propoxyphene, R,R Pseudoephedrine, Thioridazine, Cis-Tramadol, Venlafaxine hydrochloride, 8(-)-11-nor-9-Carboxy-delta-9 THC, 11-nor-9-Carboxy-delta-9-THC, Delta 8-THC, Streptomycin, Procaine, Benzocaine, Erythromycin, Penicillin G, Mepivacaine, Phendimetrazine bitartrate, Diazepam, Despropionyl fentanyl, Ethylmorphine, Nalorphine, Codeine, Morphine, Hydromorphone, Oxycodone, Cocaethylene, Cocaine, Glutethimide, Meprobamate, Methyprylon, Flurazepam, Lorazepam, Medazepam, Ternazepam, Carbamazepine, Diazepam, Nordiazepam, Oxazepam, Acetaminophen, Caffeine, Dyphylline, Methaqualone, Theophylline, Amitriptyline, Dextromethorphan, Lidocaine, Methocarbamol, Nordoxepin, Pentazocine, Phenylephrine, Triamterene, Ethosuximide, a-methyl-a-propylsuccirnide, metharbital, barbital, methsuximide, phensuximide, phensuximide, N-Normethsuximide, Mephenytoin, Ethotoin, Mephobarbital, PEMA, Phenobarbital, Methyl PEMA, 10,11-Dihydrocarbamazepine, Primidone, Carbamazepine, 5,5-Diphenylhydantoin, 4-Methylprimidone, Butabarbital, Amobarbital, Secobarbital, Hexobarbital, Phenobarbital, Medazepam, Oxazepam, Lorazepam, Diazepam, Temazepam, Bromazepam, Amitriptyline, Desipramine, Doxepin, Imipramine, Nordoxepin, Nortiptyline, Protriptyline, Trimipramine, Glutethimide, Chlorpromazine, Flurazepam.

There is the possibility that other substances and/or factors not listed above may interfere with the test and cause false results.

{6}

7

# Cosmetic Treatment

Tests were performed to determine the effects of various head hair treatments (i.e. bleaching, dyeing, relaxer, shampoo, permanent) on samples tested using the Psychemedics Microplate EIA for oxycodone. The ethnic origin, hair color and curvature were documented.

## Effects on Positive Samples:

71 specimens determined to be positive for oxycodone were used in the study. The study was conducted with two different hair treatments. Six to eight different hair samples were used for each hair treatment. ELSIA absorbance readings before and after treatment were compared. All samples determined to be positive prior to treatment remained positive post treatment.

## Effect on Negative Samples:

One hundred specimens previously determined to be negative were used in the study. The study was conducted with two different hair treatments. Ten different hair samples were used for each hair treatment. ELSIA absorbance readings before and after treatment were compared. All samples determined to be negative prior to treatment remained negative post treatment.

# Environmental Study

Preliminary positive head and body hair sample results by the screening method could be due to environmental contamination. All positive should be sent for confirmation testing on a reference method to distinguish between true positive and those samples that were positive due to external exposure.

## f. Assay cut-off:

Analytical performance of the device around the claimed cutoff is described in precision section M.1a above

## 2. Comparison studies:

### a. Method comparison with predicate device:

The study was performed by comparing ELSIA results against the LC/MS/MS results on the same head or body hair samples. A total of 161 donor hair samples were tested (64 negative and 97 positive). The results are presented in the table below:

{7}

| Opiate Test Result | Negative by GC/MS | Less than half the cutoff concentration by GC/MS | Near Cutoff Negative (Between 50% below the cutoff and the cutoff concentration) | Near Cutoff Positive (Between the cutoff and 50% above the cutoff concentration) | High Positive (Greater than 50% above the cutoff concentration) |
| --- | --- | --- | --- | --- | --- |
| Positive | 0 | 0 | 7 | 8 | 89 |
| Negative | 47 | 4 | 6 | 0 | 0 |
| Screening Cutoff (ng/10 mg hair) | ELSIA Opiate Test Results (POS/NEG) | LC/MS/MS Drug Result (pg/ 10 mg hair) |
| --- | --- | --- |
| 2 | POS | 1.16 oxycodone |
| 2 | POS | 1.28 oxycodone and hydrocodone |
| 2 | POS | 1.46 oxycodone and hydrocodone |
| 2 | POS | 1.78 oxycodone and hydrocodone |
| 2 | POS | 1.95 oxycodone and hydrocodone |
| 2 | POS | 1.95 oxycodone |
| 2 | POS | 1.96 oxycodone |

b. Matrix comparison:

Not applicable. The assay is intended for only one sample matrix.

3. Clinical studies:

a. Clinical Sensitivity:

Not applicable.

b. Clinical specificity:

Not applicable.

c. Other clinical supportive data (when a. and b. are not applicable):

Not applicable.

{8}

4. Clinical cut-off:
Not applicable.

5. Expected values/Reference range:
Not applicable.

N. Proposed Labeling:
The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

O. Conclusion:
The submitted information in this premarket notification is complete and supports a substantial equivalence decision.

9